The rapid detection and identification of Mycobacterium tuberculosis complex (MTC) in respiratory samples are extremely important for optimal diagnosis and effective treatment, as well as for prevention and control of tuberculosis transmission. Various molecular tests based on amplification and detection techniques have been devised for the detection of MTC in clinical samples (2, 14) , such as the PCR-based COBAS AMPLICOR Mycobacterium system (Roche Diagnostics, Basel, Switzerland) (4-7), the transcription-mediated amplification-based Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test system (Gen-Probe Inc., San Diego, CA) (5, 15, 16) , the strand displacement amplification-based BDProbeTec ET system (Becton Dickinson, Franklin Lakes, NJ) (6, 8) , and the ligase chain reaction-based Abbott LCx Mycobacterium tuberculosis assay system (Abbott Laboratories, North Chicago, IL) (1). While they are much more rapid than any culture-based method, these systems still require several hours to get results and involve some complicated procedures (14) . Therefore, a faster molecular test with greater ease of manipulation as well as high sensitivity and specificity is desirable.
Recently, we have reported on a novel method designated the transcription-reverse transcription concerted (TRC) method (9) . This method, a schematic of which is shown in Fig. 1 , is based on isothermal RNA amplification at 43°C with transcriptase and reverse transcriptase in the presence of the intercalation activating fluorescence (INAF) probe (10) . Measurement of the fluorescence intensity of the reaction mixture with a dedicated multicolor detector enables completely homogeneous real-time monitoring of the amplification of specific RNA, while it requires only 30 min for simultaneous amplification and detection. We have used the TRC method to establish a system for the detection of specific mRNA transcripts: tdh and trh of Vibrio parahaemolyticus (13) , mecA of methicillin-resistant Staphylococcus aureus (11) , and pab of M. tuberculosis (9, 19) .
This report concerns the establishment and evaluation of the TRC method-based targeting of MTC 16S rRNA (hereinafter abbreviated the "TRC method") for the direct detection of MTC in clinical respiratory samples. rRNA was chosen as the target to enable highly selective and sensitive detection because of its multicopy nature in a single cell. The sensitivity and specificity of the TRC method were compared with those of the COBAS AMPLICOR PCR for the direct detection of MTC in sputum samples.
MATERIALS AND METHODS
Preparation of standard RNAs for calibration. Standard RNA containing the target region for TRC amplification was prepared by the in vitro transcription of the SP6 promoter-bearing double-stranded DNA as the template for SP6 RNA polymerase. The DNA templates were synthesized from the total DNA extracted from the Mycobacterium bovis BCG strain (TOKYO 172; purchased from the National Institute of Infectious Diseases, Tokyo, Japan) by means of PCR (30 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 3 min) with a pair of synthetic oligonucleotide primers, 5Ј-CGG TAC CCA TTT AGG TGA CAC  TAT AGA ATA CAA GTT TTG TTT GGA GAG TTT GAT CC-3Ј and  5Ј-CGG TAC CCC TAC AGA CAA GAA CCC CTC A-3Ј . The long primer has the SP6 RNA polymerase-binding sequence at its 5Ј end (underlined) to provide the preferred transcription initiation site.
The amplified gene sequence was cloned into the EcoRI site of pUC19. The plasmid DNAs were then digested with EcoRI to yield linear DNAs containing the SP6 promoter, followed by in vitro transcription in a reaction mixture composed of 40 mM Tris-HCl (pH 7.5), 6 mM MgCl 2 , 2 mM spermidine, 10 mM dithiothreitol, 0.5 mM nucleoside triphosphates, 0.1 mg/ml of bovine serum albumin, 1 U/ml of RNase inhibitor, 2.5 U/ml of SP6 RNA polymerase (TaKaRa Bio, Otsu, Shiga, Japan), and 0.025 mg/ml of template DNA. The resultant RNAs were purified by gel filtration with Chromaspin-100 columns (BD Biosciences, Palo Alto, CA). The concentration of the purified RNA was determined spectrophotometrically at an optical density at 260 nm and adjusted to 10 2 to 10 7 copies/5 ml with TE (Tris-EDTA) buffer containing 0.25 U/ml of RNase inhibitor and 5 mM dithiothreitol. The RNAs were then stored at Ϫ20°C until use. TRC method for detection of M. tuberculosis complex. The principles of amplification and fluorescence-based detection have been described elsewhere (9) . Briefly, 20 l of the TRC buffer, consisting of a mixture of the substrate solution and the primer solution at a 1:1 (vol/vol) ratio, was added to 5 l of the nucleic acid extract in a thin-walled PCR tube (Applied Biosystems, Foster City, CA). The basic composition of the reaction mixture was the same as that described previously (9) , with the exception of a slight modification consisting of the omission of RNase H. The tube was then set in the dedicated instrument, a TRCR-160 real-time monitor (Tosoh Co., Tokyo, Japan), for 5 min while being preheated to 43°C, followed by the addition of 5 l of the enzyme solution. The TRCR-160 real-time monitor consists of a square incubator block maintained at 43°C and a sliding fluorescence scanning unit. The latter comprises a lightemitting diode light source to irradiate the excitation light (470 nm) from below into the tube from the bottom and a light guide to collect the fluorescence from the bottom of the reaction tube in two photomultiplier tubes (520 nm and 610 nm) at 1-min intervals. The reaction time required for fluorescence enhancement to reach a cutoff value of 1.2 was adopted as the detection time for the TRC assay. The samples for which the detection time was Յ30 min were considered to have a positive signal, and those with positive signals at 520 nm were judged to be positive. Samples without a positive signal at 520 nm and with a positive signal at 610 nm were considered negative, and those with negative signals at both 520 nm and 610 nm were considered indeterminate.
Sample processing for detection of MTC in experimental sputum samples by TRC method. Mycobacterium culture-negative, clinical sputum specimens were obtained from patients diagnosed as not having mycobacterial infection at Kyoto University Hospital, Kyoto, Japan. The samples were mixed and homogenized by vigorous vortexing and were decontaminated by treatment with N-acetyl-L-cysteine (NALC)-NaOH. Various amounts of M. bovis BCG (10 0 to 10 4 cells per 100 l), M. avium (10 2 to 10 6 cells per 100 l), and M. kansasii (10 2 to 10 6 cells per 100 l) were added to these culture-negative sputum specimens. Pretreatment consisted of mixing of 100 l of the decontaminated samples with 500 l of 67 mM phosphate buffer (pH 8.6) containing glass beads. After centrifugation at 3,000 ϫ g for 5 min at room temperature, the supernatant was removed, followed by the addition of 300 l of extraction buffer containing 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.25 U/l RNase inhibitor, and 1 mM dithiothreitol. After sonication for 5 min, followed by centrifugation at 3,000 ϫ g for 5 min, 5 l of the supernatant was used as the template.
Sample processing for detection of MTC in clinical sputum samples by culture, TRC method, and COBAS AMPLICOR PCR. Clinical samples were obtained from patients diagnosed with or suspected of having a mycobacterial infection at the National Central Hospital for Chest Disease, Osaka, Japan, and the National Tokyo Hospital, Tokyo, Japan. All samples were decontaminated by treating them by a commercially available NALC-NaOH-based method, CC-E Nichibi (Japan BCG Laboratory, Tokyo, Japan) or BBL Micoprep (Becton Dickinson, Franklin Lakes, NJ). After centrifugation at 3,000 ϫ g for 15 min at room temperature, the sediment was resuspended in 1.0 ml of phosphate buffer (pH 7.0). A smear of the decontaminated suspension was stained with the Ziehl-Neelsen stain, and a 500-l aliquot of the suspension was cultivated in the BACTEC MGIT 960 liquid culture system (Becton Dickinson) for 6 weeks, in accordance with the manufacturer's recommendations. The remaining decontaminated suspension of the samples was immediately used or was stored at Ϫ20°C until use. The TRC method was applied to 100 l of the suspension; the Roche COBAS AMPLICOR PCR was applied to 200 l of the suspension, which had been treated with the Amplicor Mycobacterium Specimen Pretreatment Set II (Roche Diagnostics). The isolated mycobacteria were identified by an immunochromatographic assay with the anti-MPB64 antibody (Capillia; Becton Dickinson), a chemiluminescent DNA hybridization probe assay (AccuProbe; Gen-Probe Inc.), or a DNA hybridization assay (DDH Mycobacteria; Kyokuto Pharmaceutical Co., Tokyo, Japan).
RESULTS
Sensitivity and specificity of TRC assay with experimental samples. In the experiment with the standard RNA calibrator for the TRC assay (Fig. 3) , the time to detection depended on the initial copy number, which ranged from 10 2 to 10 5 . For the internal control, the time to detection at 610 nm remained approximately constant at about 10 min, irrespective of the initial copy number. The results for MTC detection in experimental sputum samples containing BCG by the TRC method are shown in Table 1 . The detection limit for BCG was one organism per 100 l of sputum, and the time to detection became shorter for samples with a lower number of BCG organisms. All of the sputum samples containing Ն10 2 M. avium or M. kansasii organisms per 100 l were judged to be negative by the TRC method ( Table 1 ). The species specificity of the TRC method was examined by testing the 16S rRNA solution with 16 mycobacterial species other than MTC as the templates. The TRC method did not show positivity for any of the 16S rRNAs Comparison of TRC assay and COBAS AMPLICOR PCR for detection of MTC in clinical sputum samples. As shown in Table 2 , the COBAS AMPLICOR PCR detected as positive 41 of 43 smear-positive, culture-positive samples (sensitivity, 95.3%) and 17 of 29 smear-negative, culture-positive samples (sensitivity, 58.6%), for a total of 58 of 72 culture-positive samples (sensitivity, 80.6%). The COBAS AMPLICOR PCR produced no positive results for any of the 129 culture-negative samples (specificity, 100%). There were thus no significant differences in sensitivity and specificity between TRC and PCR, although the sample size was comparatively small for the detection of small differences in sensitivity between the two methods. The correlation of the results of the TRC method and the COBAS AMPLICOR PCR are shown in Table 3 , with the overall agreement between TRC and PCR being 95.0% (191 of 201 samples).
DISCUSSION
In this study, we were able to demonstrate that the performance of the TRC method for the detection of MTC from respiratory samples was comparable to that of the COBAS AMPLICOR PCR in terms of sensitivity and specificity. The TRC method detected as little as one BCG organism per 100 l of sputum. The selection of rRNA as the amplification target, of which a single cell contains multiple copies, may be the primary reason for this favorable result.
In the case of MTC smear-negative and culture-positive samples, the TRC method showed substantially lower rates of positivity than it did for smear-and culture-positive samples, as did the COBAS AMPLICOR PCR. This less favorable result was, however, comparable to the results of previous studies that evaluated nucleic acid amplification assays in similar settings (18) . As for the specificity, the TRC method did not show positivity for 10 6 M. avium or 10 6 M. kansasii organisms per 100 l of sputum, nor did it show positivity for 10 6 initial copies of 16S rRNA of 16 non-MTC mycobacterial species. The 129 MTC culture-negative samples comprised 40 samples which were culture positive for nontuberculous mycobacterial isolates as well as 89 mycobacterial culture-negative samples. These results clearly demonstrate the excellent specificity of the TRC method for the detection of MTC.
As to sensitivity, the difference between the two methods was not significant, although the comparatively small sample size provided this study with insufficient power to detect small differences in sensitivity. The slightly smaller number of MTC culture-positive samples detected by the TRC method than by the COBAS AMPLICOR PCR may have been due to a reduction in the numbers of viable cells during treatment, since this study included samples from patients undergoing antituberculosis chemotherapy. The levels of mycobacterial rRNA may therefore have decreased faster than the levels of DNA in proportion to the decrease in viable cells. This finding may, rather, indicate some advantage of the TRC method over DNA-based amplification methods in terms of greater correct- (12) . We found unaccountable false-negative results, four by the TRC method and two by the COBAS AMPLICOR PCR, among the 43 smear-and culture-positive samples. The reason could not be that no viable cells remained in the samples, since MTC was indeed identified by smear as well as culture of these samples. The promptly appearing positive signal of the internal control with the use of either method excluded the possibility that inhibitors were present in the samples. The slightly greater number of false-negative results obtained by the TRC method could be explained by a reduction in the number of viable cells during treatment, although the exact reason is difficult to identify. The fact that these false-negative results were found with the use of both methods together, however, makes it less likely that there are any critical problems specific to the TRC method in terms of false-negative results.
The samples examined in this study showed a prevalence of MTC-positive samples considerably higher than the prevalence in most clinical laboratories in developed nations. This is not surprising, since Japan is characterized by a substantially higher prevalence of tuberculosis compared with that in other developed countries: 24.8 new cases per million population in 2003 (11) . In addition, public health policies in Japan have been promoting the concentration of tuberculosis patients in core referral centers specializing in tuberculosis, which include the Kinki-Chuo Chest Medical Center and National Tokyo Hospital.
Of special importance are the several advantages that the TRC method has over the other nucleic acid amplification tests. First, an internal control is amplified to avoid falsenegative results; second, the entire procedure is conducted in a completely homogeneous and isothermal format, thus eliminating contamination by postamplification analysis; and third, the results from the time that the samples are decontaminated are available within an hour because amplification and detection require only 30 min. The TRC method also proved to be clinically useful for the rapid identification of MTC in respiratory samples, at least for those smear-positive ones, as is the case for COBAS AMPLICOR PCR.
Pulmonary tuberculosis and nontuberculous mycobacterial infection are sometimes difficult to differentiate based on clinical findings. The nucleic acid amplification test, which could detect MTC only, may add little information in such cases if the result was negative. Development of the TRC method for the detection of M. avium complex and M. kansasii, which is now in progress in the laboratory at Tosoh Corporation, could further enhance the clinical usefulness of this method for the management of patients with suspected mycobacterial infection especially when the smear result is positive.
In summary, the sensitivity of the TRC method was found to be comparable to that of the COBAS AMPLICOR PCR, and its specificity was excellent. Moreover, less than an hour was required to obtain results after the specimens had been treated with NALC-NaOH. This novel method can thus be expected to be suitable for routine use for the rapid diagnosis of tuberculosis.
